iTeos Therapeutics rises after reporting narrower-than-expected quarterly loss

Shares of cancer drug developer iTeos Therapeutics ITOS.O rise 4.5% to $7.15 in the afternoon trade

Company reports Q4 net loss of $1.01 per share, compared to analysts' estimates of a loss of $1.06 per share, according to data compiled by LSEG

ITOS expects its cash balance of $655 million to provide a runway through 2027

ITOS down 38.2% in the past 12 months